Ozone as a complement therapy in the treatment of COVID-19
DOI:
https://doi.org/10.33233/rbfe.v19i2.4116Resumo
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) called "coronavirus 2019" (COVID-19), has become a threat to the general population and health professionals worldwide [1]. The clinical features of COVID-19 is like that of other respiratory viruses, with specifically, fever, generally dry cough, tiredness and, in more severe cases, dyspnea, pulmonary bleeding, severe lymphopenia and renal failure [2].
For diagnosis, the World Health Organization (WHO) recommends the collection of samples from the upper or lower respiratory tract. In the laboratory, the amplification of the genetic material extracted from the saliva or mucus sample is carried out by means of a reverse transcription followed by a polymerase chain reaction (RT-PCR), which involves the synthesis of a double-stranded DNA molecule from of an RNA template, in the search for conserved parts of the coronavirus genetic code. In patients with a confirmed diagnosis, the laboratory test should be repeated to assess the release of viral particles, before leaving the isolation [3].
 The clinical manifestation and severity of the disease is directly related to the health condition of the infected individual. Symptoms are often mild as in a common cold or flu and it can progress to pneumonia. Ventilatory support therapy such as oxygen therapy and/or mechanical ventilation is necessary as an intervention method in the most severe cases of the disease [4]. Individuals with chronic respiratory diseases and other comorbidities can present the most severe form of COVID-19 and, for this reason, care with prevention should be emphasized [5]...
Referências
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020;55(3):1-9. https://doi.org/10.1016/j.ijantimicag.2020.105924
Strabelli TMV, Uip DE. COVID-19 e o coração. Arq Bras Cardiol 2020. https://doi.org/10.36660/abc.20200209
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, evaluation and treatment coronavirus (COVID-19). 2020 Apr 06. [Actualization 2020 Apr 06; cited 2020 Apr 22]. http://www.ncbi.nlm.nih.gov/books/NBK554776/#article-52171.s8
Brasil. Diretrizes para diagnóstico e tratamento da COVID-19. BrasÃlia: Ministério da Saúde; 2020. [Cited 2020 Abril 22]. https://portalarquivos.saude.gov.br/images/pdf/2020/April/13/Diretrizes-COVID-13-4.pdf
Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J 2020. [ahead of print].
Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis 2020;95:183-191. https://doi.org/10.1016/j.ijid.2020.03.013
Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020 :105938 https://doi.org/10.1016/j.ijantimicag.2020.105938
Kang S, Peng W, Zhu Y, Lu S, Zhou M, Lin W et al. Recent Progress in understanding 2019 novel coronavirus associated with human respiratory disease: detection, mechanism and treatment. Int J Antimicrob Agents 2020:105950. https://doi.org/10.1016/j.ijantimicag.2020.105950
Gordon CJ, Tchesnokov EP, Feng JY, Porter D.P, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavÃrus. J Biol Chem 2020;295915):4773-9. https://doi.org/10.1074/jbc.ac120.013056
Elvis AM, Ekta JS. Ozone therapy: A clinical review. J Nat Sci Biol Med 2011;2(1):66-70. https://doi.org/10.4103/0976-9668.82319
Sciorsci RL, Lillo E, Occhiogrosso L, Rizzo A. Ozone therapy in veterinary medicine: a review. Res Vet Sci 2020;130:240-6. https://doi.org/10.1016/j.rvsc.2020.03.026
Viebahn-Hänsler R. The use of ozone in medicine: mechanisms of action. Munich. 2003. [cited 2020 Abril 23]. http://www.altered-states.net/barry/update247/TheUseofOzoneinMedicine.pdf
Clavo B, Esparragón FR, Abreu DR, Sánchez GM, Llontop P, Bujanda DA et al. Modulation of oxidative stress by ozone therapy in the prevention and treatment of chemotherapy-induced toxicity: review and prospects. Antioxidants 2019;8(12):588. https://doi.org/10.3390/antiox8120588
Hudson JB, Sharma M, Vimalanathan S. Development of a practical method for using ozone gas as a virus decontaminating agent. Ozone Sci Eng 2009;31(3):216-23. https://doi.org/10.1080/01919510902747969
Madu IG, Belouzard S, Whittaker GR. SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion. Virology 2009;393:265-71. https://doi.org/10.1016/j.virol.2009.07.038
Hernández A, Papadakos PJ, Torres A, González DA, Vives M, Ferrando C et al. Dos terapias conocidas podrÃan ser efectivas como adyuvantes en el paciente crÃtico infectado por COVID-19. Rev Esp Anestesiol Reanim 2020 Apr 14. [ahead of print]. https://doi.org/10.1016/j.redar.2020.03.004
ISCO3. Potential use of ozone in SARS-CoV-2/COVID-19. Madri; 2020 March 14. International Scientific Committee of Ozone Therapy ISCO3. [cited 2020 April 5]. DisponÃvel em: http://www.isco3.org
Guangjian N, Hongzhi Y. Clinical study for ozonated autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19). Tianjin, 2020 Feb. 24. Tianjin University. [cited 2020 April 6]. http://www.chictr.org.cn/showproj.aspx?proj=49947
Huiling H, Tong X. A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19). Tianjin, 2020 Feb 23. Tianjin University. [Acesso em 2020 April 6]. http://www.chictr.org.cn/showprojen.aspx?proj=49747
Downloads
Publicado
Edição
Seção
Licença
Autores que publicam nesta revista concordam com os seguintes termos: Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista; Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista; Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado (Veja O Efeito do Acesso Livre).